Oxford BioDynamics (LON:OBD) Sets New 12-Month Low – Here’s Why

Oxford BioDynamics Plc (LON:OBD)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 0.08 and last traded at GBX 0.12, with a volume of 242467219 shares traded. The stock had previously closed at GBX 0.15.

Oxford BioDynamics Stock Performance

The company has a market cap of £5.15 million, a P/E ratio of -0.15 and a beta of 0.42. The stock has a 50 day moving average price of GBX 0.19 and a two-hundred day moving average price of GBX 0.23. The company has a quick ratio of 2.80, a current ratio of 0.88 and a debt-to-equity ratio of 457.97.

Oxford BioDynamics (LON:OBD) last released its quarterly earnings results on Tuesday, June 30th. The biotechnology company reported GBX (0.10) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative net margin of 1,018.54% and a negative return on equity of 316.67%. The firm had revenue of GBX 69 million during the quarter.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.